BridgeBio Pharma Inc (BBIO): Next-Year EPS Estimate 69.62%
As of 2026-11-12, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 69.62%. Featured in our EPS revision report on 2026-07-09.
On 2026-11-03, analyst consensus for BBIO's next-year EPS growth shifted from 70.19% to 69.62% — a negative change of 0.57 percentage points. The revised estimate has been sustained across 9 subsequent trading sessions. Current-year growth is projected at 29.15%.
What's Driving This
The EPS estimate revision is the
Generated 2026-11-12 from news as of 2026-11-12
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 69.62%
- EPS growth this year
- 29.15%
- EPS next quarter (est)
- -$0.58
- Last price
- $78.17
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 69.62% | 29.15% | -$0.58 | $78.17 |
| 2026-11-11 | 69.62% | 29.15% | -$0.58 | $79.54 |
| 2026-11-10 | 69.62% | 29.15% | -$0.58 | $78.67 |
| 2026-11-09 | 69.62% | 29.15% | -$0.58 | $77.93 |
| 2026-11-07 | 69.62% | 29.15% | -$0.58 | $74.29 |
| 2026-11-06 | 69.62% | 29.15% | -$0.58 | $74.29 |
| 2026-11-05 | 69.62% | 29.15% | -$0.58 | $74.27 |
| 2026-11-04 | 69.62% | 29.15% | -$0.58 | $77.89 |
| 2026-11-03 | 69.62% | 29.15% | -$0.58 | $74.03 |
| 2026-11-02 | 70.19% | 28.45% | -$0.59 | $75.00 |
| 2026-10-31 | 70.52% | 27.57% | -$0.59 | $74.95 |
| 2026-10-30 | 70.52% | 27.57% | -$0.59 | $74.95 |
| 2026-10-29 | 83.42% | 26.96% | -$0.52 | $70.73 |
| 2026-10-28 | 83.42% | 26.96% | -$0.54 | $70.82 |
| 2026-10-27 | 83.42% | 26.96% | -$0.54 | $69.37 |
| 2026-10-26 | 83.42% | 26.96% | -$0.54 | $68.15 |
| 2026-10-23 | 84.58% | 27.23% | -$0.54 | $68.56 |
| 2026-10-22 | 84.58% | 27.23% | -$0.54 | $68.12 |
| 2026-10-21 | 89.77% | 26.54% | -$0.54 | $67.74 |
| 2026-10-20 | 90.56% | 26.54% | -$0.54 | $67.55 |
| 2026-10-19 | 90.57% | 26.54% | -$0.55 | $67.94 |
| 2026-10-16 | 94.90% | 26.62% | -$0.57 | $66.39 |
| 2026-10-15 | 94.90% | 26.62% | -$0.57 | $67.13 |
| 2026-10-14 | 95.14% | 26.64% | -$0.56 | $64.94 |
| 2026-10-13 | 97.61% | 26.70% | -$0.58 | $63.30 |
| 2026-10-12 | 101.21% | 26.91% | -$0.59 | $65.75 |
| 2026-10-11 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-10 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-09 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-08 | 102.52% | 26.27% | -$0.61 | $65.04 |
Reports Featuring BBIO
Recent News
- Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CMGlobeNewswire
- BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CMGlobeNewswire
- Hershey Company Upgraded, Toast, Inc. Downgraded: Updated Rankings on Top Blue-Chip StocksInvestorPlace
- BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026GlobeNewswire
- Exelixis, Valaris, and 3 More Stocks See Action From Activist InvestorsBarrons.com
- BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder BaseGlobeNewswire
- BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing ShareholderGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...GuruFocus.com
- BridgeBio Pharma, Inc. Q2 2026 Earnings Call SummaryMoby
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-11-12, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 69.62%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-11-03, when analysts adjusted the next-year EPS growth estimate from 70.19% to 69.62%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.